Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

The ERBB network: at last, cancer therapy meets systems biology.

Yarden Y, Pines G.

Nat Rev Cancer. 2012 Jul 12;12(8):553-63. doi: 10.1038/nrc3309. Review.

PMID:
22785351
2.

Lipid rafts and the local density of ErbB proteins influence the biological role of homo- and heteroassociations of ErbB2.

Nagy P, Vereb G, Sebestyén Z, Horváth G, Lockett SJ, Damjanovich S, Park JW, Jovin TM, Szöllosi J.

J Cell Sci. 2002 Nov 15;115(Pt 22):4251-62.

3.

Small molecule inhibitors of the class 1 receptor tyrosine kinase family.

Cockerill GS, Lackey KE.

Curr Top Med Chem. 2002 Sep;2(9):1001-10. Review.

PMID:
12171567
4.

miRNAs: mediators of ErbB family targeted therapy resistance.

Adem BF, Bastos NR, Dias F, Teixeira AL, Medeiros R.

Pharmacogenomics. 2016 Jul;17(10):1175-1187. Epub 2016 Jun 30. Review.

PMID:
27359187
5.

ERBB oncogene proteins as targets for monoclonal antibodies.

Polanovski OL, Lebedenko EN, Deyev SM.

Biochemistry (Mosc). 2012 Mar;77(3):227-45. doi: 10.1134/S0006297912030029. Review.

PMID:
22803941
6.

Targeting ErbB receptors in high-grade glioma.

Berezowska S, Schlegel J.

Curr Pharm Des. 2011;17(23):2468-87. Review.

PMID:
21827413
7.

Therapeutic monoclonal antibodies for the ErbB family of receptor tyrosine kinases.

Zhang H, Richter M, Greene MI.

Cancer Biol Ther. 2003 Jul-Aug;2(4 Suppl 1):S122-6. Review.

PMID:
14508089
8.

Biological significance of c-erbB family oncogenes in head and neck cancer.

Rogers SJ, Harrington KJ, Rhys-Evans P, O-Charoenrat P, Eccles SA.

Cancer Metastasis Rev. 2005 Jan;24(1):47-69. Review.

PMID:
15785872
9.

Pharmacometrics and systems biology in oncology: is there an intersection?

Kloft C.

Int J Clin Pharmacol Ther. 2013 Jan;51(1):89-90. No abstract available.

10.

Effector mechanisms of therapeutic antibodies against ErbB receptors.

Peipp M, Dechant M, Valerius T.

Curr Opin Immunol. 2008 Aug;20(4):436-43. doi: 10.1016/j.coi.2008.05.012. Epub 2008 Jul 1. Review.

PMID:
18585454
11.

EGF-ERBB signalling: towards the systems level.

Citri A, Yarden Y.

Nat Rev Mol Cell Biol. 2006 Jul;7(7):505-16. Review.

PMID:
16829981
12.

Targeting ERBB receptors in cancer.

Hynes NE.

Recent Results Cancer Res. 2007;172:45-57. Review. No abstract available.

PMID:
17607935
13.
14.

Stratified medicine for cancer therapy.

Shaw EC, Johnson PW.

Drug Discov Today. 2012 Mar;17(5-6):261-8. Review.

PMID:
22493785
15.

Network systems biology for targeted cancer therapies.

Zhou TT.

Chin J Cancer. 2012 Mar;31(3):134-41. doi: 10.5732/cjc.011.10282. Epub 2011 Dec 16. Review.

16.

Tissue- and transformation-specific phosphotyrosyl proteins in v-erbB-transformed cells.

McManus MJ, Connolly DC, Maihle NJ.

J Virol. 1995 Jun;69(6):3631-8.

17.

Forthcoming receptor tyrosine kinase inhibitors.

Choong NW, Cohen EE.

Expert Opin Ther Targets. 2006 Dec;10(6):793-7.

PMID:
17105367
18.

Beyond histology: translating tumor genotypes into clinically effective targeted therapies.

Meador CB, Micheel CM, Levy MA, Lovly CM, Horn L, Warner JL, Johnson DB, Zhao Z, Anderson IA, Sosman JA, Vnencak-Jones CL, Dahlman KB, Pao W.

Clin Cancer Res. 2014 May 1;20(9):2264-75. doi: 10.1158/1078-0432.CCR-13-1591. Epub 2014 Mar 5. Review.

19.

The ErbB/HER family of protein-tyrosine kinases and cancer.

Roskoski R Jr.

Pharmacol Res. 2014 Jan;79:34-74. doi: 10.1016/j.phrs.2013.11.002. Epub 2013 Nov 20. Review.

PMID:
24269963
20.

Axl kinase as a key target for oncology: focus on small molecule inhibitors.

Feneyrolles C, Spenlinhauer A, Guiet L, Fauvel B, Daydé-Cazals B, Warnault P, Chevé G, Yasri A.

Mol Cancer Ther. 2014 Sep;13(9):2141-8. doi: 10.1158/1535-7163.MCT-13-1083. Epub 2014 Aug 19. Review. Erratum in: Mol Cancer Ther. 2015 Jun;14(6):1518.

Supplemental Content

Support Center